TST-006

N/A

Report date: 2024/07/02 10:11:55

Base Information

Drug NameTST-006

Drug Alias NameTST-006TST006

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-CLDN18Programmed death-ligand 1 blockers

TargetsClaudin-18 splice variant 2Programmed death-ligand 1

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesSuzhou Transcenta Therapeutics Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Transcenta Therapeutics Co Ltd

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A